Business
Eli Lilly Stock Pops As Diabetes, Obesity Drug Sales Blow Past Expectations
Eli Lilly (LLY) stock charged into a buy zone Wednesday helped by “another exceptional quarter” that featured strength from its tirzepatide-based drugs for type 2 diabetes and weight loss. Mounjaro, the diabetes treatment that uses tirzepatide, brought in $9.94 billion in sales, more than $1 billion ahead of forecasts for $8.93 billion. Obesity treatment Zepbound generated $4.93 billion in sales,…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login